Despite considerable research and clinical efforts, we remain deprived of unequivocal data clarifying the precise link between PDL-1 expression levels on tumor cells or on tumor-infiltrating immune cells and clinical responses to CPIs (Herbst et al., 2014). Here, CD274 is linked to neoplasm.